<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200613</url>
  </required_header>
  <id_info>
    <org_study_id>SCI Pilot RCT</org_study_id>
    <nct_id>NCT03200613</nct_id>
  </id_info>
  <brief_title>Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury</brief_title>
  <official_title>Apixaban Versus Low-Molecular Weight Heparin For Thromboprophylaxis In Patients With Acute Spinal Cord Injury: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thromboprophylaxis options are limited for patients with acute spinal cord injury (SCI) and&#xD;
      there are no studies on direct oral anticoagulants (DOACs) for thromboprophylaxis in this&#xD;
      population. Participants will be randomized to apixaban 2.5 mg twice daily or standard dose&#xD;
      low-molecular-weight heparin (LMWH), either enoxaparin 40 mg or dalteparin 5000 units,&#xD;
      subcutaneously once daily for 90 days or until fully mobilized, whatever comes first.&#xD;
      Thromboprophylaxis will be started as soon as hemostasis is achieved. The primary outcome for&#xD;
      this pilot study will be the recruitment rate per year (i.e. the screened to enrolled ratio).&#xD;
      The primary efficacy endpoint will be a composite of symptomatic, objectively verified,&#xD;
      venous thromboembolism (VTE), defined as upper or lower limb deep vein thrombosis (DVT)&#xD;
      and/or pulmonary embolism (PE) or sudden death where PE cannot be excluded. The primary&#xD;
      safety endpoint will be major bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute (SCI) have a high risk of VTE despite thromboprophylaxis. The current&#xD;
      standard thrombprophylaxis is to use LMWH fas soon as hemostasis is achieved. The duration of&#xD;
      thromboprophylaxis is commonly 3 months. This entails once or twice daily subcutaneous&#xD;
      injections of LMWH for the patients for this duration, which is inconvenient for the&#xD;
      patients. There are currently no studies on use of DOACs for thromboprophylaxis in patients&#xD;
      with SCI.&#xD;
&#xD;
      We will perform a pilot study at Hamilton General on apixaban versus LMWH for&#xD;
      thromboprophylaxis in patients with acute SCI. Upon providing written informed consent,&#xD;
      eligible patients will be randomized to apixaban 2.5 mg twice daily or LMWH, either&#xD;
      enoxaparin 40 mg or dalteparin 5000 units, subcutaneously once daily for 90 days or until&#xD;
      fully mobilized, whatever comes first.&#xD;
&#xD;
      The primary outcome for the feasibility study will be the recruitment rate per year (i.e. the&#xD;
      screened to enrolled ratio). Other key feasibility measures will be accrual ratio, protocol&#xD;
      violations pertaining to eligibility criteria and randomization procedures, retention rate&#xD;
      for primary end-point assessment at 1 year, and the estimates of endpoint rates in the&#xD;
      population. The primary efficacy endpoint will be a composite of symptomatic, objectively&#xD;
      verified VTE (upper or lower limb DVT and/or PE) or sudden death where PE cannot be excluded.&#xD;
      The primary safety endpoint will be major bleeding.&#xD;
&#xD;
      This will be the first study comparing the use of LMWH against a DOAC in SCI patients. Use of&#xD;
      a DOAC such as apixaban can eliminate the burden associated with daily injections for the&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study not feasible due to too slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary feasibility outcome: recruitment rate per year (i.e. the screened to enrolled ratio)</measure>
    <time_frame>24 months</time_frame>
    <description>The investigators define success as the ability to identify 20 eligible patients at each center per 12-month period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Symptomatic Venous Thromboembolism or Sudden Death Where Pulmonary Embolism Cannot be Excluded</measure>
    <time_frame>24 months</time_frame>
    <description>A composite of symptomatic, objectively verified VTE (upper or lower limb DVT and/or PE) or sudden death where PE cannot be excluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Major bleeding according to the International Society on Thrombosis and Haemostasis definition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 2.5 mg orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Molecular Weight Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>2.5 mg orally twice daily</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily</description>
    <arm_group_label>Low Molecular Weight Heparin</arm_group_label>
    <other_name>Lovenox or Fragmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥18 years old) with acute spinal cord injury (SCI) presenting to the&#xD;
             hospital within 1 week of SCI and is at least 36 h after the injury&#xD;
&#xD;
          -  Traumatic SCI&#xD;
&#xD;
          -  SCI with or without other injuries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Already on therapeutic oral anticoagulation prior to enrollment&#xD;
&#xD;
          -  Active bleeding, intracranial or perispinal hematoma, or acquired or congenital&#xD;
             bleeding disorder&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Severe renal failure (creatinine clearance ≤30 ml/min)&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Severe thrombocytopenia (platelets &lt;50)&#xD;
&#xD;
          -  Attending physician believes that the patient is not suitable for the study (for&#xD;
             example, psychiatric disorder; history of non-compliance)&#xD;
&#xD;
          -  Geographic inaccessibility: planned transfer to other site where follow-up not&#xD;
             possible&#xD;
&#xD;
          -  Failure to obtain written consent&#xD;
&#xD;
          -  Previous hypersensitivity reaction to study drugs&#xD;
&#xD;
          -  Patients with expected short hospital admission (≤7 days) due to minor injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://ashpublications.org/blood/article/134/Supplement_1/2434/422916/Apixaban-Versus-Dalteparin-for-Thromboprophylaxis</url>
    <description>Abstract for poster</description>
  </link>
  <reference>
    <citation>Piran S, Schulman S. Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. Thromb Res. 2016 Nov;147:97-101. doi: 10.1016/j.thromres.2016.09.030. Epub 2016 Oct 3.</citation>
    <PMID>27721141</PMID>
  </reference>
  <reference>
    <citation>Piran S, Schulman S. Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review. Semin Thromb Hemost. 2019 Mar;45(2):150-156. doi: 10.1055/s-0039-1678720. Epub 2019 Feb 11. Review.</citation>
    <PMID>30743281</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Sam Schulman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Spinal cord injury</keyword>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

